The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Topiramate in Migraine Prevention: Results of a Large Controlled Trial
Abstract
BACKGROUND: Open-label trials and small controlled studies report topiramate's efficacy in migraine prevention. OBJECTIVE: To assess the efficacy and safety of topiramate as a migraine-preventive therapy. DESIGN: A 26-week, randomized, double-blind, placebo-controlled study. SETTING: Outpatient treatment at 49 US clinical centers. Patients Patients were aged 12 to 65 years, had a 6-month International Headache Society migraine history, and experienced 3 to 12 migraines per month, but had 15 or fewer headache days per month during the 28-day baseline period. INTERVENTIONS: Participants were randomized to placebo or topiramate, 50, 100, or 200 mg/d, titrated by 25 mg/wk to the assigned dose or as tolerated in 8 weeks; maintenance therapy continued for 18 weeks. MAIN OUTCOME MEASURES: The primary efficacy assessment was a reduction in mean monthly migraine frequency across the 6-month treatment phase. Secondary end points were responder rate, time to onset of action, mean change in migraine days per month, and mean change in rescue medication days per month. RESULTS: Four hundred eighty-seven patients were randomized, and 469 composed the intent-to-treat population. The mean +/- SD monthly migraine frequency decreased significantly for the 100-mg/d group (from 5.4 +/- 2.2 to 3.3 +/- 2.9; P <.001) and the 200-mg/d group (from 5.6 +/- 2.6 to 3.3 +/- 2.9; P <.001) vs the placebo group (from 5.6 +/- 2.3 to 4.6 +/- 3.0); improvements occurred within the first treatment month. Significantly more topiramate-treated patients (50 mg/d, 35.9% [P =.04]; 100 mg/d, 54.0% [P <.001]; and 200 mg/d, 52.3% [P <.001]) exhibited a 50% or more reduction in monthly migraine frequency than placebo-treated patients (22.6%). Adverse events included paresthesia, fatigue, nausea, anorexia, and taste per version. CONCLUSION: Topiramate, 100 or 200 mg/d, was effective as a preventive therapy for patients with migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Silberstein, S. D. (2000) · Neurology · doi:10.1212/wnl.55.6.754 · Cited by 1,360
Self-citationOral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Testing the Statistical Certainty of a Response to Increasing Doses of a Drug
Tukey, J. W., Ciminera, J. L., & Heyse, J. F. (1985) · Biometrics · doi:10.2307/2530666 · Cited by 486
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Amitriptyline in Migraine Prophylaxis
Couch, J. R., & Hassanein, R. S. (1979) · Archives of Neurology · doi:10.1001/archneur.1979.00500470065013 · Cited by 334
Migraine Prophylaxis With Divalproex
Mathew, N. T., Saper, J. R., Silberstein, S. D., Rankin, L., Markley, H. G., Solomon, S., Rapoport, A. M., Silber, C. J., & Deaton, R. L. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540270077022 · Cited by 329
Self-citationDivalproex Sodium in Migraine Prophylaxis: A Dose-Controlled Study
Klapper, J., & on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1702103.x · Cited by 280
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis
Freitag, F. G., Collins, S. D., Carlson, H. A., Goldstein, J., Saper, J., Silberstein, S., Mathew, N., Winner, P. K., Deaton, R., & Sommerville, K. (2002) · Neurology · doi:10.1212/wnl.58.11.1652 · Cited by 274
Self-citationSilberstein, S. D., Upton, R. B., & Goadsby, P. J. (2018) · Routledge eBooks · doi:10.4324/9780203752210 · Cited by 256
Self-citationHoopes, S. P., Reimherr, F. W., Hedges, D. W., Rosenthal, N. R., Kamin, M., Karim, R., Capece, J. A., & Karvois, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1109 · Cited by 211
Berlant, J., & van Kammen, D. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0104 · Cited by 200
Guidelines for Controlled Trials of Drugs in Migraine. First Edition
(1991) · Cephalalgia · doi:10.1046/j.1468-2982.1991.1101001.x · Cited by 189
Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial
Tfelt‐Hansen, P. C., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J. (1984) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1984.tb07772.x · Cited by 146
A double-blind placebo-controlled trial of topiramate treatment for essential tremor
Connor, G. S. (2002) · Neurology · doi:10.1212/wnl.59.1.132 · Cited by 132
Topiramate: A Case Series Study in Migraine Prophylaxis
Young, W., Hopkins, M., Shechter, A. L., & Silberstein, S. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00380.x · Cited by 58
Self-citation
Cited by
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
Self-citationEFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Chronic migraine: risk factors, mechanisms and treatment
May, A., & Schulte, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.93 · Cited by 630
Suppression of cortical spreading depression in migraine prophylaxis
Ayata, C., Jin, H., Kudo, C., Dalkara, T., & Moskowitz, M. A. (2006) · Annals of Neurology · doi:10.1002/ana.20778 · Cited by 570
Diener, H.-C., Bussone, G., Oene, J. V., Lahaye, M., Schwalen, S., & Goadsby, P. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01326.x · Cited by 561
Metadata
- Authors
- Silberstein, S. D.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2004-04-01
- Volume
- 61
- Issue
- 4
- Pages
- 490
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1973511428
- Cited by
- 529
- References
- 18
- FWCI
- 32.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.